ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial

ORIC Pharmaceuticals announced promising Phase 1b data for enozertinib in first-line EGFR atypical NSCLC patients, demonstrating 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with an 88% 6-month landmark PFS. The company plans to initiate the Redwood-1 global Phase 3 registrational trial in 1H 2027, enrolling approximately 360 patients.